INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 48 filers reported holding INOZYME PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $56 | -41.1% | 13,375 | -21.8% | 0.00% | – |
| Q2 2023 | $95 | -90.5% | 17,100 | +14515.4% | 0.00% | – |
| Q2 2022 | $1,000 | -93.8% | 117 | -96.9% | 0.00% | – |
| Q1 2022 | $16,000 | -38.5% | 3,834 | 0.0% | 0.00% | – |
| Q4 2021 | $26,000 | -78.5% | 3,834 | -63.3% | 0.00% | – |
| Q3 2021 | $121,000 | -19.3% | 10,453 | +18.8% | 0.00% | – |
| Q2 2021 | $150,000 | -38.5% | 8,802 | -28.4% | 0.00% | – |
| Q1 2021 | $244,000 | +59.5% | 12,300 | +66.2% | 0.00% | – |
| Q4 2020 | $153,000 | – | 7,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $27,113,000 | 10.69% |
| Burrage Capital Management LLC | 242,517 | $4,132,000 | 4.14% |
| CHI Advisors LLC | 927,264 | $15,801,000 | 3.68% |
| Sofinnova Investments, Inc. | 2,028,308 | $34,562,000 | 1.99% |
| Novo Holdings A/S | 1,867,706 | $31,826,000 | 1.41% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,178,985 | $37,130,000 | 0.66% |
| RA Capital Management | 2,003,653 | $34,142,000 | 0.55% |
| NEA Management Company, LLC | 2,444,379 | $41,652,000 | 0.54% |
| Rock Springs Capital Management LP | 840,272 | $14,318,000 | 0.28% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 365,172 | $6,223,000 | 0.09% |